Qualigen Therapeutics (QLGN) 10-Q 13 May 22 2022 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2022	May 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-37428
Entity Registrant Name	Qualigen Therapeutics, Inc.
Entity Central Index Key	0001460702
Entity Tax Identification Number	26-3474527
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2042 Corte Del Nogal
Entity Address, City or Town	Carlsbad
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92011
City Area Code	(760)
Local Phone Number	918-9165
Title of 12(b) Security	Common Stock, par value $.001 per share
Trading Symbol	QLGN
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		35,295,541

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets
Cash	$ 13,610,894	$ 17,538,272
Accounts receivable, net	594,338	822,351
Inventory, net	1,400,712	1,055,878
Prepaid expenses and other current assets	1,097,822	1,379,896
Total current assets	16,703,766	20,796,397
Right-of-use assets	1,591,072	1,645,568
Property and equipment, net	230,242	203,920
Equipment held for lease, net	221	296
Intangible assets, net	164,818	171,190
Other assets	18,334	18,334
Total Assets	18,708,453	22,835,705
Current liabilities
Accounts payable	997,406	886,224
Accrued expenses and other current liabilities	1,343,375	1,793,901
Deferred revenue, current portion	127,304	135,063
Operating lease liability, current portion	155,525	134,091
Warrant liabilities	1,002,100	1,686,200
Total current liabilities	3,625,710	4,635,479
Operating lease liability, net of current portion	1,484,833	1,542,564
Deferred revenue, net of current portion	81,081	92,928
Total liabilities	5,191,624	6,270,971
Stockholders’ equity
Common stock, $0.001 par value; 225,000,000 shares authorized; 35,295,541 and 35,290,178 shares issued and outstanding as of March 31, 2022 and December 31, 2021, respectively	35,295	35,290
Additional paid-in capital	102,545,950	101,274,073
Accumulated deficit	(89,064,416)	(84,744,629)
Total stockholders’ equity	13,516,829	16,564,734
Total Liabilities & Stockholders’ Equity	$ 18,708,453	$ 22,835,705

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	225,000,000	225,000,000
Common stock, shares issued	35,295,541	35,290,178
Common stock, shares outstanding	35,295,541	35,290,178

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
REVENUES
Total revenues	$ 722,029	$ 1,899,496
EXPENSES
Cost of product sales	828,848	1,202,479
General and administrative	2,898,751	2,873,939
Research and development	1,864,745	3,499,373
Sales and marketing	138,323	136,587
Total expenses	5,730,667	7,712,378
LOSS FROM OPERATIONS	(5,008,638)	(5,812,882)
OTHER (INCOME), NET
Gain on change in fair value of warrant liabilities	(683,242)	(552,808)
Interest income, net	(6,309)	(17,343)
Other income, net	(36)	(542)
Total other income, net	(689,587)	(570,693)
LOSS BEFORE PROVISION FOR INCOME TAXES	(4,319,051)	(5,242,189)
PROVISION FOR INCOME TAXES	736	530
NET LOSS	$ (4,319,787)	$ (5,242,719)
Net loss per common share, basic and diluted	$ (0.12)	$ (0.19)
Weighted—average number of shares outstanding, basic and diluted	35,294,051	28,165,796
Net Product Sales [Member]
REVENUES
Total revenues	$ 722,029	$ 1,420,842
License Revenue [Member]
REVENUES
Total revenues	$ 0	$ 478,654

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)	Preferred Stock [Member]Series Alpha Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning Balance at Dec. 31, 2020	$ 1	$ 27,296	$ 85,114,755	$ (66,847,492)	$ 18,294,560
Beginning balance, shares at Dec. 31, 2020	180	27,296,061
Stock issued upon exercise of warrants		$ 1,320	1,813,353		1,814,673
Stock issued upon cash-exercise of warrants, shares		1,319,625
Stock-based compensation			1,262,123		1,262,123
Net Loss				(5,242,719)	(5,242,719)
Stock issued upon net-exercise of warrants		$ 192	(192)
Stock issued upon net-exercise of warrants, shares		192,373
Stock issued for professional services		$ 25	101,725		101,750
Stock issued for professional services, shares		25,000
Ending Balance at Mar. 31, 2021	$ 1	$ 28,833	88,291,764	(72,090,211)	16,230,387
Ending balance, shares at Mar. 31, 2021	180	28,833,059
Beginning Balance at Dec. 31, 2021		$ 35,290	101,274,073	(84,744,629)	16,564,734
Beginning balance, shares at Dec. 31, 2021		35,290,178
Stock issued upon exercise of warrants		$ 5	4,711		4,716
Stock issued upon cash-exercise of warrants, shares		5,363
Stock-based compensation			1,267,166		1,267,166
Net Loss				(4,319,787)	(4,319,787)
Ending Balance at Mar. 31, 2022		$ 35,295	$ 102,545,950	$ (89,064,416)	$ 13,516,829
Ending balance, shares at Mar. 31, 2022		35,295,541

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (4,319,787)	$ (5,242,719)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	29,749	27,453
Amortization of right-of-use assets	54,495	54,179
Accounts receivable reserves and allowances	(88,129)	8,490
Inventory reserves	4,074	29,615
Common stock issued for professional services		101,750
Stock-based compensation	1,267,166	1,262,123
Change in fair value of warrant liabilities	(683,242)	(552,808)	$ 300,000
Changes in operating assets and liabilities:
Accounts receivable	316,142	(254,968)
Inventory and equipment held for lease	(348,908)	107,588
Prepaid expenses and other assets	282,074	1,459,135
Accounts payable	111,184	(15,217)
Accrued expenses and other current liabilities	(450,526)	1,122,686
Operating lease liability	(36,297)	(60,710)
Deferred revenue	(19,606)	(127,701)
Net cash used in operating activities	(3,881,611)	(2,081,104)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(49,625)	(62,265)
Payments for patents and licenses		(6,737)
Net cash used in investing activities	(49,625)	(69,002)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from warrant exercises	3,858	244,581
Principal payments on notes payable		(123,133)
Net cash provided by financing activities	3,858	121,448
Net change in cash	(3,927,378)	(2,028,658)
Cash - beginning of period	17,538,272	23,976,570	23,976,570
Cash - end of period	13,610,894	21,947,912	$ 17,538,272
Cash paid during the year for:
Interest		831
Taxes		100
NONCASH FINANCING AND INVESTING ACTIVITIES:
Fair value of shares issued for cashless warrant exercises		722,970
Fair value of warrant liabilities on date of exercise	$ 858	$ 1,570,092

ORGANIZATION AND SUMMARY OF SIG

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES	NOTE 1 — ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES Organization Qualigen, Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the “Company”) operates in one business segment. In May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (“Ritter”) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.’s capital stock were exchanged for Qualigen Therapeutics, Inc.’s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol “RTTR,” commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol “QLGN” on May 26, 2020. Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities Exchange Commission on March 31, 2022, as amended on April 29, 2022 (the “2021 Annual Report”). In the opinion of management, the accompanying condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s 2021 Annual Report have been omitted. The accompanying condensed consolidated balance sheet at December 31, 2021 has been derived from the audited balance sheet at December 31, 2021 contained in the 2021 Annual Report. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All long-lived assets of the Company are located in the United States. Accounting Estimates Management uses estimates and assumptions in preparing its unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. Actual results could vary from the estimates that were used. Cash The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains its cash in bank deposits which exceed federally insured limits and could potentially be subject to significant concentrations of credit risk on cash. The Company reviews the financial stability of its depository institutions on a regular basis, and has not experienced any losses in such accounts. Inventory, Net Inventory is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified as excess or obsolete. Long-Lived Assets The Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. During the three months ended March 31, 2022 and 2021, no Accounts Receivable, Net The Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without recourse to the Company. The Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The Company’s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable. Accounts receivable, net is comprised of the following at: SCHEDULE OF ACCOUNTS RECEIVABLE March 31, 2022 December 31, 2021 Accounts Receivable $ 642,306 $ 958,448 Less Allowances (47,968 ) (136,097 ) Accounts receivable, net $ 594,338 $ 822,351 Research and Development The Company expenses research and development costs as incurred including therapeutics license costs. Shipping and Handling Costs The Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and outbound freight are generally recorded in cost of sales which totaled approximately $ 39,000 30,000 4,000 1,000 Revenue from Contracts with Customers We apply the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Product Sales The Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System. Disposable products include reagent packs which are diagnostic tests for prostate-specific antigen (“PSA”), testosterone, thyroid disorders, pregnancy, and Vitamin D. The Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable products using separate purchase orders after the equipment (“analyzer”) has been provided to the customer. The initial delivery of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days. The performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The disposable products are shipped Free on Board (“FOB”) shipping point. For disposable products that are shipped FOB shipping point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave the Company’s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time. The Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to fulfill the promise to transfer the disposable products and not as a separate performance obligation. The Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company’s contracts. License Revenue The Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable upfront license fees and/or sales-based royalties. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. During the three months ended March 31, 2022 and 2021, the Company recognized license revenue of $ 0 479,000 Contract Asset and Liability Balances The timing of the Company’s revenue recognition may differ from the timing of payment by the Company’s customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are satisfied. Multiple performance obligations included contracts that combined both the Company’s analyzer and a customer’s future reagent purchases under a single contract. In some sales contracts, the Company provided analyzers at no charge to customers. Title to the analyzer was maintained by the Company and the analyzer was returned by the customer to the Company at the end of the purchase agreement. During the three months ended March 31, 2022 and 2021, product sales are stated net of an allowance for estimated returns of approximately $ 43,000 0 Deferred Revenue Payments received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the time from the condensed consolidated balance sheets date to the future date of revenue recognition. Operating Leases Effective April 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2018-11, Leases (Topic 842) Targeted Improvements Property and Equipment, Net Property and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful lives of the related assets as follows: SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT Machinery and equipment 5 Computer equipment 3 Molds and tooling 5 Furniture and fixtures 5 Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until the relevant assets are completed and placed in service. The Company’s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when conditions are present that indicate impairment. Intangible Assets, Net Intangibles consist of patent-related costs and costs for license agreements. Management reviews the carrying value of intangible assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered. If the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible assets as impaired and reduces them by a charge to operations in the amount of the impairment. Costs related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally 5 17 The carrying value of the patents of approximately $ 154,000 159,000 325,000 320,000 5,000 3,000 14,000 18,000 15,000 14,000 79,000 The carrying value of the in-licenses of approximately $ 11,000 12,000 408,000 407,000 2,000 6,000 5,000 Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7). Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: ● Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; ● Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and ● Level 3 - Inputs that are unobservable. Fair Value of Financial Instruments Cash, accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments. Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant. Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years. Sales and Excise Taxes Sales and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with corresponding tax payable. These balances are removed from the condensed consolidated balance sheet as cash is collected from customers and remitted to the tax authority. Warranty Costs The Company’s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in the period in which the revenue is recognized based on historical data and the Company’s best estimates of analyzer failure rates and costs to repair. Accrued warranty liabilities were approximately $ 72,000 60,000 53,000 25,000 Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) Leases (Topic 842) Impact of the COVID-19 Pandemic Events surrounding the SARS-CoV-2 virus that emerged in late 2019 and the ensuing global pandemic have had a dramatic impact on businesses globally and our business as well. Our sales of diagnostic products fell significantly during 2020 and our net loss increased significantly, as deferral of patients’ non-emergency visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand. The severity and duration of the pandemic and economic repercussions of the virus and government actions taken in response to the pandemic remain uncertain and will ultimately depend on many factors, including the speed of global dissemination and effectiveness of the vaccination and containment efforts throughout the world, the duration and spread of the virus, as well as seasonality, variants or new outbreaks. In the United States, federal, state, and local government directives and policies have been put in place throughout the course of the pandemic to manage public health concerns and address the economic impacts of the pandemic, including reduced business activity and overall uncertainty presented by this new healthcare challenge. Similar actions have been taken by governments around the world. Our facilities could be required to temporarily curtail production levels or temporarily cease operations based on government mandates or as a result of the pandemic. To mitigate risks, we continue to evaluate the extent to which COVID-19 may impact our business and operations and adjust risk mitigation planning and business continuity activities as needed. Other accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s unaudited condensed financial statements.

LIQUIDITY

LIQUIDITY	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY	NOTE 2 — LIQUIDITY The Company has incurred recurring losses from operations and has an accumulated deficit at March 31, 2022. The Company expects to continue to incur losses subsequent to the condensed consolidated balance sheet date of March 31, 2022. In December 2021, the Company raised $ 8.82 million through a Securities Purchase Agreement with several institutional investors. Based on the Company’s current cash position, and assuming currently planned expenditures and level of operations, the Company believes it has sufficient capital to fund operations for the 12-month period subsequent to the issuance of the accompanying unaudited condensed financial statements. However, there is no assurance that profitable operations will ever be achieved, or if achieved, could be sustained on a continuing basis. Also, beyond such 12-month period, planned research and development activities, capital expenditures, clinical and pre-clinical testing, and commercialization activities of the Company’s products are expected to require significant additional financing. Additional financing may not be available on acceptable terms or at all.

INVENTORY, NET

INVENTORY, NET	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
INVENTORY, NET	NOTE 3 — INVENTORY, NET Inventory, net consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF INVENTORY March 31, 2022 December 31, 2021 Raw materials $ 819,434 $ 823,315 Work in process 539,085 188,135 Finished goods 42,193 44,428 Total inventory $ 1,400,712 $ 1,055,878

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	3 Months Ended
	Mar. 31, 2022
Prepaid Expenses And Other Current Assets
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 4 — PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2022 December 31, 2021 Prepaid insurance $ 818,216 $ 1,197,726 Prepaid manufacturing expenses 32,087 50,371 Other prepaid expenses 247,519 131,799 Prepaid expenses $ 1,097,822 $ 1,379,896

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT, NET	NOTE 5 — PROPERTY AND EQUIPMENT, NET Property and equipment, net consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2022 December 31, 2021 Machinery and equipment $ 2,493,222 $ 2,482,841 Computer equipment 384,361 345,117 Leasehold improvements 333,271 333,271 Molds and tooling 260,002 260,002 Furniture and fixtures 143,013 143,013 Property and equipment, gross 3,613,869 3,564,244 Less Accumulated depreciation (3,383,627 ) (3,360,324 ) Property and equipment, net $ 230,242 $ 203,920 Depreciation expense relating to property and equipment was approximately $ 23,000 15,000

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	NOTE 6 — ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES March 31, 2022 December 31, 2021 Board compensation $ 17,500 $ 17,500 Franchise, sales and use taxes 11,975 14,090 Income taxes 4,356 3,620 Payroll 105,877 682,036 Professional fees 265,421 225,308 Research and development 293,624 232,712 Royalties 8,880 10,152 Vacation 313,633 282,910 Warranty liability 71,974 60,281 Other 250,135 265,292 Accrued liabilities $ 1,343,375 $ 1,793,901

WARRANT LIABILITIES

WARRANT LIABILITIES	3 Months Ended
	Mar. 31, 2022
Warrant Liabilities
WARRANT LIABILITIES	NOTE 7 – WARRANT LIABILITIES In 2004, the Company issued warrants to various investors and brokers for the purchase of Series C preferred stock in connection with a private placement (the “Series C Warrants”). The Series C Warrants were subsequently extended and, upon closing of the reverse recapitalization transaction with Ritter, exchanged for warrants to purchase common stock of the Company, pursuant to the Series C Warrant terms as adjusted. In exchange for the Series C Warrants, upon closing of the merger with Ritter, the holders received warrants to purchase an aggregate of 4,713,490 0.72 1.7 2.2 The following table summarizes the activity in the Common Stock Warrants (received in exchange for the Series C Warrants) for the three months ended March 31, 2022: SCHEDULE OF WARRANTS ACTIVITY Common Stock Warrants (received in exchange for the Series C Warrants) Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 2,481,614 $ 0.72 2.00 Exercised (5,363 ) 0.72 Forfeited — — Expired — — Granted — — Total outstanding – March 31, 2022 2,476,251 $ 0.72 Exercisable 2,476,251 $ 0.72 $ 0.72 1.76 The following table summarizes the activity in the Common Stock Warrants (received in exchange for the Series C Warrants) activity for the three months ended March 31, 2021: Common Stock Warrants (received in exchange for the Series C Warrants) Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding –December 31, 2020 3,378,596 $ 0.72 Exercised (473,608 ) 0.72 Forfeited (36,097 ) 0.72 Expired — — Granted — — Total outstanding – March 31, 2021 2,868,891 $ 0.72 Exercisable 2,868,891 $ 0.72 $ 0.72 2.75 The following table presents the Company’s fair value hierarchy for its warrant liabilities and exercises (all of which arise under the warrants received in exchange for the Series C Warrants) measured at fair value on a recurring basis using Level 3 inputs as of March 31, 2022: SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES Quoted Market Significant Prices for Other Significant Identical Observable Unobservable Common Stock Warrant Assets Inputs Inputs liabilities (Level 1) (Level 2) (Level 3) Total Balance as of December 31, 2021 $ — $ — $ 1,686,200 $ 1,686,200 Exercises — — (858 ) (858 ) Gain on change in fair value of warrant liabilities — — (683,242 ) (683,242 ) Balance as of March 31, 2022 $ — $ — $ 1,002,100 $ 1,002,100 There were no transfers of financial assets or liabilities between category levels for the three months ended March 31, 2022. The value of the warrant liabilities was based on a valuation received from an independent valuation firm determined using a Monte-Carlo simulation. For volatility, the Company considers comparable public companies as a basis for its expected volatility to calculate the fair value of common stock warrants and transitions to its own volatility as the Company develops sufficient appropriate history as a public company. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the common stock warrant. The Company uses an expected dividend yield of zero based on the fact that the Company has never paid cash dividends and does not expect to pay cash dividends in the foreseeable future. Any significant changes in the inputs may result in significantly higher or lower fair value measurements. The following table shows the range of assumptions used in estimating the fair value of warrant liabilities as of March 31, 2022 and 2021: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES March 31, 2022 March 31, 2021 Range Weighted Average Range Weighted Average Risk-free interest rate 2.03 2.29 % 2.08 % 0.28 0.42 % 0.30 % Expected volatility (peer group) 88 101 % 90.4 % 81 84 % 83.52 % Term of warrants (in years) 1.65 2.24 1.76 2.65 3.24 2.75 Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 %

LOSS PER SHARE

LOSS PER SHARE	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
LOSS PER SHARE	NOTE 8 — LOSS PER SHARE Basic loss per share (“EPS”) is computed by dividing net loss by the weighted-average number of common shares outstanding. Diluted EPS is computed based on the sum of the weighted-average number of common shares and potentially dilutive common shares outstanding during the period. Potentially dilutive common shares consist of shares issuable from stock options and warrants. The following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods: SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED For the Three Months Ended March 31, For the Three Months Ended March 31, 2022 2021 Net loss used for basic earnings per share $ (4,319,787 ) $ (5,242,719 ) Basic weighted-average common shares outstanding 35,294,051 28,165,796 Dilutive potential shares issuable from stock options and warrants — — Diluted weighted-average common shares outstanding 35,294,051 28,165,796 The following potentially dilutive securities have been excluded from diluted net loss per share as of March 31, 2022 and 2021 because their effect would be antidilutive: SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE For the Three Months Ended For the Three Months Ended 2022 2021 Shares of common stock subject to outstanding options 4,864,023 4,033,856 Shares of common stock subject to outstanding warrants 9,816,032 9,609,316 Shares of common stock subject to conversion of Series Alpha Convertible Preferred Stock — 243,418 Total common stock equivalents 14,680,055 13,886,590

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 — COMMITMENTS AND CONTINGENCIES Leases The Company leases its facilities under a long-term operating lease agreement. On December 15, 2021, our wholly-owned subsidiary Qualigen, Inc. entered into a Second Amendment to Lease with Bond Ranch LP. This Amendment extended the Company’s triple-net leasehold on the Company’s existing 22,624 61 November 1, 2022 to November 30, 2027 1,950,710 335,966 339,360 The tables below show the operating lease right-of-use assets and operating lease liabilities as of March 31, 2022, including the changes during the periods: SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES Operating lease right-of-use assets Net right-of-use assets at December 31, 2021 $ 1,645,568 Less amortization of operating lease right-of-use assets (54,496 ) Operating lease right-of-use assets at March 31, 2022 $ 1,591,072 Operating lease liabilities Lease liabilities at December 31, 2021 $ 1,676,655 Less principal payments on operating lease liabilities (36,297 ) Lease liabilities at March 31, 2022 1,640,358 Less non-current portion (1,484,833 ) Current portion at March 31, 2022 $ 155,525 As of March 31, 2022, the Company’s operating leases have a weighted-average remaining lease term of 5.6 years and a weighted-average discount rate of 8.9 %. As of March 31, 2022, future minimum payments during the next five fiscal years and thereafter are as follows: SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES Year Ending December 31, Amount 2022 (nine months) $ 203,857 2023 368,341 2024 379,392 2025 390,773 2026 402,497 2027 379,165 Total 2,124,025 Less present value discount (483,667 ) Operating lease liabilities $ 1,640,358 Total lease expense was approximately $ 114,000 86,000 Termination of Sekisui Distribution Agreement In March 2018, the Company extended a strategic partnership entered into in May 2016 with Sekisui Diagnostics, LLC (“Sekisui”). The Company appointed Sekisui as its diagnostics commercial partner and exclusive worldwide distributor with the exception of certain customer accounts retained by Qualigen; Sekisui’s distribution arrangement expired on March 31, 2022. Subsequent to the expiration of the agreement, in the second quarter of 2022 the Company will have a commitment to purchase leased FastPack rental systems back from Sekisui at Sekisui’s net book value, the amount of which has not yet been determined. Litigation and Other Legal Proceedings On November 9, 2021, the Company was named as a defendant in an action brought by Mediant Communications Inc. (“Mediant”) in the U.S. District Court for the Southern District of New York. The complaint alleged that Qualigen entered into an implied contract with Mediant, whereby Qualigen retained Mediant to distribute proxy materials and subsequently conduct shareholder vote tabulations. The Company filed a Motion to Dismiss with the District Court and on March 14, 2022 a hearing was held during which the presiding judge ruled in favor of the Motion to Dismiss. The Company and Mediant settled the litigation on April 5, 2022 in the amount of $ 96,558 . This amount is included in accounts payable and accrued expenses on the Company’s March 31, 2022 condensed consolidated balance sheet.

RESEARCH AND LICENSE AGREEMENTS

RESEARCH AND LICENSE AGREEMENTS	3 Months Ended
	Mar. 31, 2022
Research And License Agreements
RESEARCH AND LICENSE AGREEMENTS	NOTE 10 — RESEARCH AND LICENSE AGREEMENTS The University of Louisville Research Foundation Between June 2018 and April 2022, the Company entered into license and sponsored research agreements with the University of Louisville Research Foundation (“ULRF”) for QN-247, a novel aptamer-based compound that has shown promise as an anticancer drug. Under the agreements, the Company will take over development, regulatory approval and commercialization of the compound from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received a $ 50,000 convertible promissory note in payment of an upfront license fee, which was subsequently converted into the Company’s common stock, and the Company agreed to reimburse ULRF for sponsored research expenses of up to approximately $ 805,000 and prior patent costs of up to $ 200,000 . In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $ 100,000 to $ 5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $ 100,000 for first dosing in a Phase 1 clinical trial, $ 200,000 for first dosing in a Phase 2 clinical trial, $ 350,000 for first dosing in a Phase 3 clinical trial, $ 500,000 for regulatory marketing approval and $ 5,000,000 upon achieving a cumulative $ 500,000,000 of Licensed Product sales; the Company would also pay another $ 500,000 milestone payment for any additional regulatory marketing approval for each additional therapeutic (or diagnostic) indication. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $ 10,000 to $ 50,000 ) for such year. Sponsored research expenses related to these agreements for the three months ended March 31, 2022 and 2021 were approximately $ 87,000 62,000 55,000 36,000 In March 2019, the Company entered into a sponsored research agreement and an option for a license agreement with ULRF for development of several small-molecule RAS interaction inhibitor drug candidates. Under the terms of this agreement, the Company agreed to reimburse ULRF for sponsored research expenses of up to $ 693,000 for this program. In February 2021 and March 2022, the Company extended the term of this agreement until January 2023 and increased the amount that the Company will reimburse ULRF for sponsored research expenses to approximately $ 2.7 million. In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $ 50,000 to $ 5,000,000 upon the achievement of certain regulatory and commercial milestones. Milestone payments for the first therapeutic indication would be $ 50,000 for first dosing in a Phase 1 clinical trial, $ 100,000 for first dosing in a Phase 2 clinical trial, $ 150,000 for first dosing in a Phase 3 clinical trial, $ 300,000 for regulatory marketing approval and $ 5,000,000 upon achieving a cumulative $ 500,000,000 of Licensed Product sales. The Company also must pay ULRF shortfall payments if the total amounts actually paid with respect to royalties and non-royalty sublicensee income for any year is less than the applicable annual minimum (ranging from $ 20,000 to $ 100,000 ) for such year. Sponsored research expenses related to these agreements for the three months ended March 31, 2022 and 2021 were approximately $ 184,000 107,000 2,000 46,000 In June 2020, the Company entered into an exclusive license agreement with ULRF for its intellectual property in the use of QN-165 as a treatment for COVID-19. Under the agreement, the Company will take over development, regulatory approval and commercialization of the compound (for such use) from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $ 24,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company was required to enter into a separate sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) for at least $ 250,000 . In November 2020, the Company executed a sponsored research agreement with ULRF (for QN-165 as a treatment for COVID-19) supporting up to approximately $ 430,000 in research which satisfied this requirement. This sponsored research agreement expired in November 2021. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $ 50,000 5,000,000 50,000 100,000 150,000 300,000 5,000,000 500,000,000 5,000 50,000 Sponsored research expenses related to these agreements for the three months ended March 31, 2022 and 2021 were $ 0 69,000 no Advanced Cancer Therapeutics In December 2018, the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (“ACT”), granting the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate. 25,000 3,000,000 3,000,000 100,000 2,000,000 100,000 500,000 3,000,000 0 2,000 Prediction Biosciences In November 2015, the Company entered into a long-term development and supply agreement with Prediction Biosciences SAS to develop and manufacture diagnostic tests for use in the stroke point-of-care market. The Company recognizes development revenue and product sales over the performance period of the contract. For both the three months ended March 31, 2022 and 2021, there was no Sekisui Diagnostics In March 2018, the Company extended a strategic partnership entered into in May 2016 with Sekisui Diagnostics, LLC (“Sekisui”). The Company appointed Sekisui as its diagnostics commercial partner and exclusive worldwide distributor with the exception of certain customer accounts retained by Qualigen. Sekisui’s distribution arrangement expired on March 31, 2022. The agreement contains a right of first refusal for Sekisui against any potential acquisition of the Company which expired on March 31, 2022. There were product sales to Sekisui of approximately $ 403,000 1,017,000 Yi Xin In October 2020, the Company entered into a Technology Transfer Agreement with Yi Xin Zhen Duan Jishu (Suzhou) Ltd. (“Yi Xin”), of Suzhou, China, for Yi Xin to develop, manufacture and sell new generations of diagnostic test systems based on the Company’s core FastPack technology. In addition, the Technology Transfer Agreement authorized Yi Xin to manufacture and sell the Company’s current generations of FastPack System diagnostic products (1.0, IP and PRO) in China. The Company will receive low- to mid-single-digit royalties on any future new-generations and current-generations product sales by Yi Xin. The Company recognized $ 0 38,000 0 479,000 The Company gave Yi Xin the exclusive rights for China – which is a market the Company has not otherwise entered – both for Yi Xin’s new generations of FastPack-based products and for Yi Xin-manufactured versions of the Company’s existing FastPack product lines. Yi Xin will also have the right to sell its new generations of FastPack-based diagnostic test systems throughout the world (but not to or toward current customers of the Company’s existing generations of FastPack products). After March 31, 2022, Yi Xin has the right to sell Yi Xin-manufactured versions of existing FastPack 1.0, IP and PRO product lines worldwide (other than in the United States and other than to or toward current non-U.S. customers of those products), as well as the right to buy Company-manufactured FastPack 1.0, IP and PRO products from the Company at distributor prices for resale in and for the United States (but not to or toward current U.S. customers of those products); the Company did not license Yi Xin to sell in the United States market any Yi Xin-manufactured versions of those legacy FastPack 1.0, IP and PRO product lines. In the Technology Transfer Agreement, the Company also confirmed that it would not, after March 31, 2022, seek new FastPack customers outside the United States. STA Pharmaceutical In November 2020, the Company entered into a contract with STA Pharmaceutical Co., Ltd., a subsidiary of WuXi AppTec, for GMP production of QN-165, which was the Company’s lead drug candidate for the treatment of COVID-19 and other viral diseases, for potential clinical trials in 2021. Research and development expenses related to this agreement for the three months ended March 31, 2022 and 2021 were approximately $ 9,000 1.1 million, respectively, and are recorded in research and development expenses in the condensed consolidated statements of operations. UCL Business Limited In January 2022, the Company entered into a License Agreement with UCL Business Limited to obtain an exclusive worldwide in-license of a genomic quadruplex (G4)-selective transcription inhibitor drug development program which had been developed at University College London, including lead and back-up compounds, preclinical data and a patent estate. (UCL Business Limited is the commercialization company for University College London.) The program’s lead compound is now being developed at Qualigen under the name QN-302 as a candidate for treatment for pancreatic ductal adenocarcinoma (PDAC), which represents the vast majority of pancreatic cancers. The License Agreement requires a $ 150,000 upfront payment, reimbursement of past patent prosecution expenses (approximately $ 160,000 ), and (if and when applicable) tiered royalty payments in the low to mid-single digits, clinical/regulatory/sales milestone payments and a percentage of any non-royalty sublicensing consideration paid to Qualigen. For the three months ended March 31, 2022 and 2021, there were license costs of approximately $ 310,000 0

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2022
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 11 — STOCKHOLDERS’ EQUITY As of March 31, 2022 and December 31, 2021, the Company had two classes of capital stock: common stock and Series Alpha convertible preferred stock. Common Stock Holders of common stock generally vote as a class with the holders of the preferred stock and are entitled to one vote for each share held. Subject to the rights of the holders of the preferred stock to receive preferential dividends, the holders of common stock are entitled to receive dividends when and if declared by the Board of Directors. Following payment of the liquidation preference of the preferred stock, as of March 31, 2022 any remaining assets would be distributed ratably among the holders of the common stock and, on an as-if-converted basis, the holders of Series Alpha convertible preferred stock upon liquidation, dissolution or winding up of the affairs of the Company. The holders of common stock have no preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions. At March 31, 2022, the Company has reserved 14,680,055 At March 31, 2022, shares were reserved in connection with the following: SCHEDULE OF RESERVED SHARES Exercise of issued and future grants of stock options 4,864,023 Exercise of stock warrants 9,816,032 Total 14,680,055 Series Alpha Convertible Preferred Stock As of March 31, 2022, and December 31, 2021, there were no Stock Options and Warrants The Company recognizes all compensatory share-based payments as compensation expense over the service period, which is generally the vesting period. In April 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the granting of incentive or non statutory common stock options to qualified employees, officers, directors, consultants and other service providers. At March 31, 2022 and December 31, 2021 there were 4,770,167 and 4,748,000 outstanding options, respectively, under the 2020 Plan and on those dates there were 2,786,990 and 2,809,157 unused 2020 Plan shares available, respectively, for future grant. The shares available for future grant reflect a 2020 Plan amendment approved by the Company’s stockholders on August 9, 2021 where the number of shares of common stock available for issuance under the 2020 Plan was increased by 3,500,000 . The following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers that are outstanding at March 31, 2022, and changes during the three-month period then ended: SCHEDULE OF STOCK OPTION ACTIVITY Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 4,841,856 $ 6.07 $ 1.24 1,465.75 8.52 Granted 25,000 1.05 1.05 9.79 Expired — — — — Forfeited (2,833 ) 3.00 1.24 4.97 — Total outstanding – March 31, 2022 4,864,023 $ 6.05 $ 1.05 1,465.75 8.28 Exercisable (vested) 1,417,195 $ 10.83 $ 3.29 1,465.75 7.69 Non-Exercisable (non-vested) 3,446,828 $ 4.08 $ 1.05 5.13 8.57 There was approximately $ 1.3 6.9 1.35 Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2020 4,011,356 $ 7.05 $ 3.52 1,465.75 9.29 Granted 27,000 3.29 3.29 9.91 Expired — — — — Forfeited (4,500 ) 3.68 3.52 4.97 9.78 Total outstanding – March 31, 2021 4,033,856 $ 7.03 $ 3.29 1,465.75 9.04 Exercisable (vested) 108,856 $ 81.38 $ 4.97 1,465.75 2.26 Non-Exercisable (non-vested) 3,925,000 $ 4.96 $ 3.29 5.13 9.23 The exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the date of grant. 0.84 Fair Value of Equity Awards The Company utilizes the Black-Scholes option pricing model to value awards under its Plans. Key valuation assumptions include: ● Expected dividend yield. ● Expected stock-price volatility. ● Risk-free interest rate. ● Expected term. The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows: SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD 2022 2021 For the three months ended March 31, 2022 2021 Expected dividend yield 0.00 % 0.00 % Expected stock-price volatility 102 % 102 % Risk-free interest rate 1.58 1.67 % 0.84 1.04 % Expected average term of options (in years) 6.00 6.00 Stock price $ 1.05 $ 3.29 The Company recorded share-based compensation expense and classified it in the unaudited condensed consolidated statements of operations as follows: SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE 2022 2021 For the three months ended March 31, 2022 2021 General and administrative $ 1,113,384 $ 1,092,228 Research and development 153,782 169,895 Total $ 1,267,166 $ 1,262,123 Equity Classified Compensatory Warrants In connection with the $ 4.0 811,431 1.11 In addition, various service providers hold equity classified compensatory warrants issued in 2017 and earlier (originally exercisable to purchase Series C convertible preferred stock, and now instead exercisable to purchase common stock) for the purchase of 668,024 2.34 During the year ended December 31, 2021, the Company issued equity classified compensatory warrants to a service provider for the purchase of 600,000 1.32 0.3 No compensatory warrants were issued during the three months ended March 31, 2022. The following table summarizes the activity in the common stock equity classified compensatory warrants for the three months ended March 31, 2022: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 1,790,648 $ 1.52 $ 1.11 — $ 2.54 2.64 Granted to advisor and its designees — — Exercised — — Expired — — Forfeited — — Total outstanding – March 31, 2022 1,790,648 $ 1.52 $ 1.11 — 2.54 2.39 Exercisable 1,790,648 $ 1.52 $ 1.11 — $ 2.54 2.39 Non-Exercisable — $ — $ — — The following table summarizes the activity in the common stock equity classified compensatory warrants for the three months ended March 31, 2021: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2020 1,294,217 $ 1.66 Granted — — Exercised (38,390 ) 2.09 Expired — — Forfeited (65,179 ) 2.07 Total outstanding – March 31, 2021 1,190,648 $ 1.61 Exercisable 1,187,052 $ 1.60 $ 1.11 2.54 4.00 Non-Exercisable 3,596 $ 2.54 $ 2.54 5.48 There were no compensation costs related to outstanding equity classified compensatory warrants for the three months ended March 31, 2022 or for the three months ended March 31, 2021. As of March 31, 2022 and 2021, there were no unrecognized compensation costs related to nonvested equity classified compensatory warrants. Noncompensatory Equity Classified Warrants In May 2020, as a commitment fee, the Company issued noncompensatory equity classified warrants to an investor for the purchase of 270,478 1.11 200,000 780,198 0.001 1,920,678 5.25 1,287,829 6.00 1,000,000 0.01 2,191,010 4.07 During the year ended December 31, 2021, with the exception of the warrants to purchase 270,478 1.11 5,399,517 2.00 2.3 The following table summarizes the noncompensatory equity classified warrant activity for the three months ended March 31, 2022: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 5,549,137 $ 2.01 Legacy Ritter warrants — — Granted — — Exercised — — Expired — — Forfeited — — Total outstanding – March 31, 2022 5,549,137 $ 2.01 Exercisable 5,549,137 $ 2.01 $ 1.11 — $ 3.77 1.07 Non-Exercisable — $ — $ — —

QUARTERLY FINANCIAL DATA (UNAUD

QUARTERLY FINANCIAL DATA (UNAUDITED)	3 Months Ended
	Mar. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
QUARTERLY FINANCIAL DATA (UNAUDITED)	NOTE 12 - QUARTERLY FINANCIAL DATA (UNAUDITED) As disclosed in 2021 Annual Report, our management identified an error in the previously issued March 31, 2021, June 30, 2021 and September 30, 2021 unaudited interim condensed consolidated financial statements in which the fair value of its exercised liability classified warrants had been inadvertently excluded from reclassification into shareholders’ equity. All financial information contained in the accompanying notes to these condensed consolidated financial statements has been revised to reflect the correction of this error as shown in the table below. SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS As reported Corrected For the Quarter Ended March 31, 2021 As reported Corrected Gain on change in fair value of warrant liabilities $ (2,122,900 ) $ (552,808 ) Net loss $ (3,672,627 ) $ (5,242,719 ) Net loss per common share $ (0.13 ) $ (0.19 )

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 13 — SUBSEQUENT EVENTS On April 25, 2022, the Company amended the terms of outstanding warrants to purchase 600,000 shares of the Company’s common stock previously issued to GreenBlock, LLC on December 3, 2021 ( 300,000 0.60 per share and extend the expiration date to September 14, 2023. On April 29, 2022, the Company entered into a Series B Preferred Share Purchase Agreement (the “Series B Purchase Agreement”) with NanoSynex Ltd., a company established under the laws of the State of Israel (“NanoSynex”), pursuant to which it will acquire 381,786 newly authorized Series B preferred shares of NanoSynex, nominal value NIS 0.01 per share, for a total purchase price of $ 600,000 , subject to certain closing conditions described in the Series B Purchase Agreement. As a condition to the Series B Purchase Agreement, the Company has agreed to, among other things, enter into a Master Agreement for the Operational and Technological Funding of NanoSynex (the “Funding Agreement”), pursuant to which the Company will agree to fund NanoSynex up to an aggregate of approximately $ 10.4 million over the following three years, subject to NanoSynex’s achievement of certain performance milestones specified in the Funding Agreement and the satisfaction of other terms and conditions described in the Funding Agreement. Also on April 29, 2022, the Company entered into a Share Purchase Agreement (the “Series A-1 Purchase Agreement”) with Alpha Capital Anstalt (“Alpha”), pursuant to which it will acquire 2,232,861 0.01 3,500,000 2,432,203 Subject to the satisfaction of the applicable closing conditions set forth in the Series B Purchase Agreement and Series A-1 Purchase Agreement, the Company will acquire an approximate 53% interest in the voting securities of NanoSynex. The Company believes the NanoSynex share purchases result in a business combination which will be accounted for during the three and six months ended June 30, 2022, respectively.

ORGANIZATION AND SUMMARY OF S_2

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Policies)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization	Organization Qualigen, Inc., now a subsidiary of Qualigen Therapeutics, Inc., was incorporated in Minnesota in 1996 to design, develop, manufacture and sell point-of-care quantitative immunoassay diagnostic products for use in physician offices and other point-of-care settings worldwide, and was reincorporated in Delaware in 1999. Qualigen Therapeutics, Inc. (the “Company”) operates in one business segment. In May 2020, Qualigen, Inc. completed a reverse recapitalization transaction with Ritter Pharmaceuticals, Inc. (“Ritter”) and Ritter was renamed Qualigen Therapeutics, Inc. All shares of Qualigen, Inc.’s capital stock were exchanged for Qualigen Therapeutics, Inc.’s capital stock in the merger. Ritter/Qualigen Therapeutics common stock, which was previously traded on the Nasdaq Capital Market under the ticker symbol “RTTR,” commenced trading on the Nasdaq Capital Market, on a post-reverse-stock-split adjusted basis, under the trading symbol “QLGN” on May 26, 2020.
Basis of Presentation	Basis of Presentation The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and the rules of the Securities and Exchange Commission (“SEC”) applicable to interim reports of companies filing as a smaller reporting company. These financial statements should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 filed with the Securities Exchange Commission on March 31, 2022, as amended on April 29, 2022 (the “2021 Annual Report”). In the opinion of management, the accompanying condensed consolidated interim financial statements include all adjustments necessary in order to make the financial statements not misleading. The results of operations for interim periods are not necessarily indicative of the results to be expected for the full year or any other future period. Certain notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the most recent fiscal year as reported in the Company’s 2021 Annual Report have been omitted. The accompanying condensed consolidated balance sheet at December 31, 2021 has been derived from the audited balance sheet at December 31, 2021 contained in the 2021 Annual Report.
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All long-lived assets of the Company are located in the United States.
Accounting Estimates	Accounting Estimates Management uses estimates and assumptions in preparing its unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. The most significant estimates relate to the estimated fair value of warrant liabilities, stock-based compensation, amortization and depreciation, inventory reserves, allowances for doubtful accounts and returns, and warranty costs. Actual results could vary from the estimates that were used.
Cash	Cash The Company considers all highly liquid investments purchased with an initial maturity of 90 days or less and money market funds to be cash equivalents. The Company maintains its cash in bank deposits which exceed federally insured limits and could potentially be subject to significant concentrations of credit risk on cash. The Company reviews the financial stability of its depository institutions on a regular basis, and has not experienced any losses in such accounts.
Inventory, Net	Inventory, Net Inventory is recorded at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method. The Company reviews the components of its inventory on a periodic basis for excess or obsolete inventory, and records reserves for inventory components identified as excess or obsolete.
Long-Lived Assets	Long-Lived Assets The Company assesses potential impairments to its long-lived assets when there is evidence that events or changes in circumstances indicate that assets may not be recoverable. An impairment loss would be recognized when the sum of the expected future undiscounted cash flows is less than the carrying amount of the assets. The amount of impairment loss, if any, will generally be measured as the difference between the net book value of the assets and their estimated fair values. During the three months ended March 31, 2022 and 2021, no
Accounts Receivable, Net	Accounts Receivable, Net The Company grants credit to domestic physicians, clinics, and distributors. The Company performs ongoing credit evaluations of its customers and generally requires no collateral. Customers can purchase certain products through a financing agreement that the Company has with an outside leasing company. Under the agreement, the leasing company evaluates the credit worthiness of the customer. Upon acceptance of the product by the customer, the leasing company remits payment to the Company at a discount. This financing arrangement is without recourse to the Company. The Company records an allowance for doubtful accounts and returns equal to the estimated uncollectible amounts or expected returns. The Company’s estimates are based on historical collections and returns and a review of the current status of trade accounts receivable. Accounts receivable, net is comprised of the following at: SCHEDULE OF ACCOUNTS RECEIVABLE March 31, 2022 December 31, 2021 Accounts Receivable $ 642,306 $ 958,448 Less Allowances (47,968 ) (136,097 ) Accounts receivable, net $ 594,338 $ 822,351
Research and Development	Research and Development The Company expenses research and development costs as incurred including therapeutics license costs.
Shipping and Handling Costs	Shipping and Handling Costs The Company includes shipping and handling fees billed to customers in net sales. Shipping and handling costs associated with inbound and outbound freight are generally recorded in cost of sales which totaled approximately $ 39,000 30,000 4,000 1,000
Revenue from Contracts with Customers	Revenue from Contracts with Customers We apply the following five-step model in accordance with ASC 606, Revenue from Contracts with Customers, in order to determine the revenue: (i) identification of the promised goods or services in the contract; (ii) determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii) measurement of the transaction price, including the constraint on variable consideration; (iv) allocation of the transaction price to the performance obligations; and (v) recognition of revenue when (or as) the Company satisfies each performance obligation. Product Sales The Company generates revenue from selling FastPack System analyzers, accessories and disposable products used with the FastPack System. Disposable products include reagent packs which are diagnostic tests for prostate-specific antigen (“PSA”), testosterone, thyroid disorders, pregnancy, and Vitamin D. The Company provides disposable products and equipment in exchange for consideration, which occurs when a customer submits a purchase order and the Company provides disposable products and equipment at the agreed upon prices in the invoice. Generally, customers purchase disposable products using separate purchase orders after the equipment (“analyzer”) has been provided to the customer. The initial delivery of the equipment and reagent packs represents a single performance obligation and is completed upon receipt by the customer. The delivery of each subsequent individual reagent pack represents a separate performance obligation because the reagent packs are standardized, are not interrelated in any way, and the customer can benefit from each reagent pack without any other product. There are no significant discounts, rebates, returns or other forms of variable consideration. Customers are generally required to pay within 30 days. The performance obligation arising from the delivery of the equipment is satisfied upon the delivery of the equipment to the customer. The disposable products are shipped Free on Board (“FOB”) shipping point. For disposable products that are shipped FOB shipping point, the customer has the significant risks and rewards of ownership and legal title to the assets when the disposable products leave the Company’s shipping facilities, thus the customer obtains control and revenue is recognized at that point in time. The Company has elected the practical expedient and accounting policy election to account for the shipping and handling as activities to fulfill the promise to transfer the disposable products and not as a separate performance obligation. The Company’s contracts with customers generally have an expected duration of one year or less, and therefore the Company has elected the practical expedient in ASC 606 to not disclose information about its remaining performance obligations. Any incremental costs to obtain contracts are recorded as selling, general and administrative expense as incurred due to the short duration of the Company’s contracts. License Revenue The Company enters into out-license agreements with counterparties to develop and/or commercialize its products in exchange for nonrefundable upfront license fees and/or sales-based royalties. If the license to the Company’s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from nonrefundable upfront fees allocated to the license when the license is transferred to the customer and the customer can benefit from the license. For licenses that are bundled with other performance obligations, management uses judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from nonrefundable upfront fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of progress and related revenue recognition. During the three months ended March 31, 2022 and 2021, the Company recognized license revenue of $ 0 479,000 Contract Asset and Liability Balances The timing of the Company’s revenue recognition may differ from the timing of payment by the Company’s customers. The Company records a receivable when revenue is recognized prior to payment and there is an unconditional right to payment. Alternatively, when payment precedes the performance of the related services, the Company records deferred revenue until the performance obligations are satisfied. Multiple performance obligations included contracts that combined both the Company’s analyzer and a customer’s future reagent purchases under a single contract. In some sales contracts, the Company provided analyzers at no charge to customers. Title to the analyzer was maintained by the Company and the analyzer was returned by the customer to the Company at the end of the purchase agreement. During the three months ended March 31, 2022 and 2021, product sales are stated net of an allowance for estimated returns of approximately $ 43,000 0 Deferred Revenue Payments received in advance from customers pursuant to certain collaborative research license agreements, deposits against future product sales, multiple element arrangements and extended warranties are recorded as a current or non-current deferred revenue liability based on the time from the condensed consolidated balance sheets date to the future date of revenue recognition.
Operating Leases	Operating Leases Effective April 1, 2020, the Company adopted Accounting Standards Update (“ASU”) No. 2018-11, Leases (Topic 842) Targeted Improvements
Property and Equipment, Net	Property and Equipment, Net Property and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful lives of the related assets as follows: SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT Machinery and equipment 5 Computer equipment 3 Molds and tooling 5 Furniture and fixtures 5 Leasehold improvements are amortized on a straight-line basis over the shorter of the lease term or their estimated useful lives. The Company occasionally designs and builds its own machinery. The costs of these projects, which includes the cost of construction and other direct costs attributable to the construction, are capitalized as construction in progress. No provision for depreciation is made on construction in progress until the relevant assets are completed and placed in service. The Company’s policy is to evaluate the remaining lives and recoverability of long-term assets on at least an annual basis or when conditions are present that indicate impairment.
Intangible Assets, Net	Intangible Assets, Net Intangibles consist of patent-related costs and costs for license agreements. Management reviews the carrying value of intangible assets that are being amortized on an annual basis or sooner when there is evidence that events or changes in circumstances may indicate that impairment exists. The Company considers relevant cash flow and profitability information, including estimated future operating results, trends and other available information, in assessing whether the carrying value of intangible assets being amortized can be recovered. If the Company determines that the carrying value of intangible assets will not be recovered from the undiscounted future cash flows expected to result from the use and eventual disposition of the underlying assets, the Company considers the carrying value of such intangible assets as impaired and reduces them by a charge to operations in the amount of the impairment. Costs related to acquiring patents and licenses are capitalized and amortized over their estimated useful lives, which is generally 5 17 The carrying value of the patents of approximately $ 154,000 159,000 325,000 320,000 5,000 3,000 14,000 18,000 15,000 14,000 79,000 The carrying value of the in-licenses of approximately $ 11,000 12,000 408,000 407,000 2,000 6,000 5,000
Derivative Financial Instruments and Warrant Liabilities	Derivative Financial Instruments and Warrant Liabilities The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of its financial instruments, including issued stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the condensed consolidated statements of operations. Depending on the features of the derivative financial instrument, the Company uses either the Black-Scholes option-pricing model or a Monte-Carlo simulation to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re-assessed at the end of each reporting period (See Note 7).
Fair Value Measurements	Fair Value Measurements The Company determines the fair value measurements of applicable assets and liabilities based on a three-tier fair value hierarchy established by accounting guidance and prioritizes the inputs used in measuring fair value. The Company discloses and recognizes the fair value of its assets and liabilities using a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to valuations based upon unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to valuations based upon unobservable inputs that are significant to the valuation (Level 3 measurements). The guidance establishes three levels of the fair value hierarchy as follows: ● Level 1 - Inputs that reflect unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date; ● Level 2 - Inputs other than quoted prices that are observable for the assets or liability either directly or indirectly, including inputs in markets that are not considered to be active; and ● Level 3 - Inputs that are unobservable.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Cash, accounts receivable, prepaids, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
Stock-Based Compensation	Stock-Based Compensation Stock-based compensation cost for equity awards granted to employees and non-employees is measured at the grant date based on the calculated fair value of the award using the Black-Scholes option-pricing model, and is recognized as an expense, under the straight-line method, over the requisite service period (generally the vesting period of the equity grant). If the Company determines that other methods are more reasonable, or other methods for calculating these assumptions are prescribed by regulators, the fair value calculated for the Company’s stock options could change significantly. Higher volatility, lower risk-free interest rates, and longer expected lives would result in an increase to stock-based compensation expense to employees and non-employees determined at the date of grant.
Income Taxes	Income Taxes Deferred income taxes are recognized for temporary differences in the basis of assets and liabilities for financial statement and income tax reporting that arise due to net operating loss carry forwards, research and development credit carry forwards and from using different methods and periods to calculate depreciation and amortization, allowance for doubtful accounts, accrued vacation, research and development expenses, and state taxes. A provision has been made for income taxes due on taxable income and for the deferred taxes on the temporary differences. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Realization of the deferred income tax asset is dependent on generating sufficient taxable income in future years.
Sales and Excise Taxes	Sales and Excise Taxes Sales and other taxes collected from customers and subsequently remitted to government authorities are recorded as accounts receivable with corresponding tax payable. These balances are removed from the condensed consolidated balance sheet as cash is collected from customers and remitted to the tax authority.
Warranty Costs	Warranty Costs The Company’s warranty policy generally provides for one year of coverage against defects and nonperformance within published specifications for sold analyzers and for the term of the contract for equipment held for lease. The Company accrues for estimated warranty costs in the period in which the revenue is recognized based on historical data and the Company’s best estimates of analyzer failure rates and costs to repair. Accrued warranty liabilities were approximately $ 72,000 60,000 53,000 25,000
Recent Accounting Pronouncements	Recent Accounting Pronouncements In June 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-13, Measurement of Credit Losses on Financial Instruments Financial Instruments – Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) Leases (Topic 842)
Impact of the COVID-19 Pandemic	Impact of the COVID-19 Pandemic Events surrounding the SARS-CoV-2 virus that emerged in late 2019 and the ensuing global pandemic have had a dramatic impact on businesses globally and our business as well. Our sales of diagnostic products fell significantly during 2020 and our net loss increased significantly, as deferral of patients’ non-emergency visits to physician offices, clinics and small hospitals sharply reduced demand for FastPack tests. Since then we have experienced some recovery in demand. The severity and duration of the pandemic and economic repercussions of the virus and government actions taken in response to the pandemic remain uncertain and will ultimately depend on many factors, including the speed of global dissemination and effectiveness of the vaccination and containment efforts throughout the world, the duration and spread of the virus, as well as seasonality, variants or new outbreaks. In the United States, federal, state, and local government directives and policies have been put in place throughout the course of the pandemic to manage public health concerns and address the economic impacts of the pandemic, including reduced business activity and overall uncertainty presented by this new healthcare challenge. Similar actions have been taken by governments around the world. Our facilities could be required to temporarily curtail production levels or temporarily cease operations based on government mandates or as a result of the pandemic. To mitigate risks, we continue to evaluate the extent to which COVID-19 may impact our business and operations and adjust risk mitigation planning and business continuity activities as needed. Other accounting standard updates are either not applicable to the Company or are not expected to have a material impact on the Company’s unaudited condensed financial statements.

ORGANIZATION AND SUMMARY OF S_3

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Tables)	3 Months Ended
	Mar. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF ACCOUNTS RECEIVABLE	Accounts receivable, net is comprised of the following at: SCHEDULE OF ACCOUNTS RECEIVABLE March 31, 2022 December 31, 2021 Accounts Receivable $ 642,306 $ 958,448 Less Allowances (47,968 ) (136,097 ) Accounts receivable, net $ 594,338 $ 822,351
SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT	Property and equipment are stated at cost and are presented net of accumulated depreciation. Depreciation is provided for on a straight-line basis over the estimated useful lives of the related assets as follows: SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT Machinery and equipment 5 Computer equipment 3 Molds and tooling 5 Furniture and fixtures 5

INVENTORY, NET (Tables)

INVENTORY, NET (Tables)	3 Months Ended
	Mar. 31, 2022
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	Inventory, net consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF INVENTORY March 31, 2022 December 31, 2021 Raw materials $ 819,434 $ 823,315 Work in process 539,085 188,135 Finished goods 42,193 44,428 Total inventory $ 1,400,712 $ 1,055,878

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Mar. 31, 2022
Prepaid Expenses And Other Current Assets
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	Prepaid expenses and other current assets consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2022 December 31, 2021 Prepaid insurance $ 818,216 $ 1,197,726 Prepaid manufacturing expenses 32,087 50,371 Other prepaid expenses 247,519 131,799 Prepaid expenses $ 1,097,822 $ 1,379,896

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	3 Months Ended
	Mar. 31, 2022
Property, Plant and Equipment [Abstract]
SCHEDULE OF PROPERTY AND EQUIPMENT	Property and equipment, net consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF PROPERTY AND EQUIPMENT March 31, 2022 December 31, 2021 Machinery and equipment $ 2,493,222 $ 2,482,841 Computer equipment 384,361 345,117 Leasehold improvements 333,271 333,271 Molds and tooling 260,002 260,002 Furniture and fixtures 143,013 143,013 Property and equipment, gross 3,613,869 3,564,244 Less Accumulated depreciation (3,383,627 ) (3,360,324 ) Property and equipment, net $ 230,242 $ 203,920

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2022
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	Accrued expenses and other current liabilities consisted of the following at March 31, 2022 and December 31, 2021: SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES March 31, 2022 December 31, 2021 Board compensation $ 17,500 $ 17,500 Franchise, sales and use taxes 11,975 14,090 Income taxes 4,356 3,620 Payroll 105,877 682,036 Professional fees 265,421 225,308 Research and development 293,624 232,712 Royalties 8,880 10,152 Vacation 313,633 282,910 Warranty liability 71,974 60,281 Other 250,135 265,292 Accrued liabilities $ 1,343,375 $ 1,793,901

WARRANT LIABILITIES (Tables)

WARRANT LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2022
Warrant Liabilities
SCHEDULE OF WARRANTS ACTIVITY	The following table summarizes the activity in the Common Stock Warrants (received in exchange for the Series C Warrants) for the three months ended March 31, 2022: SCHEDULE OF WARRANTS ACTIVITY Common Stock Warrants (received in exchange for the Series C Warrants) Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 2,481,614 $ 0.72 2.00 Exercised (5,363 ) 0.72 Forfeited — — Expired — — Granted — — Total outstanding – March 31, 2022 2,476,251 $ 0.72 Exercisable 2,476,251 $ 0.72 $ 0.72 1.76 The following table summarizes the activity in the Common Stock Warrants (received in exchange for the Series C Warrants) activity for the three months ended March 31, 2021: Common Stock Warrants (received in exchange for the Series C Warrants) Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding –December 31, 2020 3,378,596 $ 0.72 Exercised (473,608 ) 0.72 Forfeited (36,097 ) 0.72 Expired — — Granted — — Total outstanding – March 31, 2021 2,868,891 $ 0.72 Exercisable 2,868,891 $ 0.72 $ 0.72 2.75
SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES	The following table presents the Company’s fair value hierarchy for its warrant liabilities and exercises (all of which arise under the warrants received in exchange for the Series C Warrants) measured at fair value on a recurring basis using Level 3 inputs as of March 31, 2022: SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES Quoted Market Significant Prices for Other Significant Identical Observable Unobservable Common Stock Warrant Assets Inputs Inputs liabilities (Level 1) (Level 2) (Level 3) Total Balance as of December 31, 2021 $ — $ — $ 1,686,200 $ 1,686,200 Exercises — — (858 ) (858 ) Gain on change in fair value of warrant liabilities — — (683,242 ) (683,242 ) Balance as of March 31, 2022 $ — $ — $ 1,002,100 $ 1,002,100
SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES	The following table shows the range of assumptions used in estimating the fair value of warrant liabilities as of March 31, 2022 and 2021: SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES March 31, 2022 March 31, 2021 Range Weighted Average Range Weighted Average Risk-free interest rate 2.03 2.29 % 2.08 % 0.28 0.42 % 0.30 % Expected volatility (peer group) 88 101 % 90.4 % 81 84 % 83.52 % Term of warrants (in years) 1.65 2.24 1.76 2.65 3.24 2.75 Expected dividend yield 0.00 % 0.00 % 0.00 % 0.00 %

LOSS PER SHARE (Tables)

LOSS PER SHARE (Tables)	3 Months Ended
	Mar. 31, 2022
Earnings Per Share [Abstract]
SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED	The following table reconciles net loss and the weighted-average shares used in computing basic and diluted EPS in the respective periods: SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED For the Three Months Ended March 31, For the Three Months Ended March 31, 2022 2021 Net loss used for basic earnings per share $ (4,319,787 ) $ (5,242,719 ) Basic weighted-average common shares outstanding 35,294,051 28,165,796 Dilutive potential shares issuable from stock options and warrants — — Diluted weighted-average common shares outstanding 35,294,051 28,165,796
SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE	The following potentially dilutive securities have been excluded from diluted net loss per share as of March 31, 2022 and 2021 because their effect would be antidilutive: SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE For the Three Months Ended For the Three Months Ended 2022 2021 Shares of common stock subject to outstanding options 4,864,023 4,033,856 Shares of common stock subject to outstanding warrants 9,816,032 9,609,316 Shares of common stock subject to conversion of Series Alpha Convertible Preferred Stock — 243,418 Total common stock equivalents 14,680,055 13,886,590

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES	SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES Operating lease right-of-use assets Net right-of-use assets at December 31, 2021 $ 1,645,568 Less amortization of operating lease right-of-use assets (54,496 ) Operating lease right-of-use assets at March 31, 2022 $ 1,591,072 Operating lease liabilities Lease liabilities at December 31, 2021 $ 1,676,655 Less principal payments on operating lease liabilities (36,297 ) Lease liabilities at March 31, 2022 1,640,358 Less non-current portion (1,484,833 ) Current portion at March 31, 2022 $ 155,525
SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES	As of March 31, 2022, future minimum payments during the next five fiscal years and thereafter are as follows: SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES Year Ending December 31, Amount 2022 (nine months) $ 203,857 2023 368,341 2024 379,392 2025 390,773 2026 402,497 2027 379,165 Total 2,124,025 Less present value discount (483,667 ) Operating lease liabilities $ 1,640,358

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	3 Months Ended
	Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF RESERVED SHARES	SCHEDULE OF RESERVED SHARES Exercise of issued and future grants of stock options 4,864,023 Exercise of stock warrants 9,816,032 Total 14,680,055
SCHEDULE OF STOCK OPTION ACTIVITY	The following represents a summary of the options granted (under the 2020 Plan and otherwise) to employees and non-employee service providers that are outstanding at March 31, 2022, and changes during the three-month period then ended: SCHEDULE OF STOCK OPTION ACTIVITY Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 4,841,856 $ 6.07 $ 1.24 1,465.75 8.52 Granted 25,000 1.05 1.05 9.79 Expired — — — — Forfeited (2,833 ) 3.00 1.24 4.97 — Total outstanding – March 31, 2022 4,864,023 $ 6.05 $ 1.05 1,465.75 8.28 Exercisable (vested) 1,417,195 $ 10.83 $ 3.29 1,465.75 7.69 Non-Exercisable (non-vested) 3,446,828 $ 4.08 $ 1.05 5.13 8.57 There was approximately $ 1.3 6.9 1.35 Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2020 4,011,356 $ 7.05 $ 3.52 1,465.75 9.29 Granted 27,000 3.29 3.29 9.91 Expired — — — — Forfeited (4,500 ) 3.68 3.52 4.97 9.78 Total outstanding – March 31, 2021 4,033,856 $ 7.03 $ 3.29 1,465.75 9.04 Exercisable (vested) 108,856 $ 81.38 $ 4.97 1,465.75 2.26 Non-Exercisable (non-vested) 3,925,000 $ 4.96 $ 3.29 5.13 9.23
SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD	The material factors incorporated in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows: SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD 2022 2021 For the three months ended March 31, 2022 2021 Expected dividend yield 0.00 % 0.00 % Expected stock-price volatility 102 % 102 % Risk-free interest rate 1.58 1.67 % 0.84 1.04 % Expected average term of options (in years) 6.00 6.00 Stock price $ 1.05 $ 3.29
SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE	The Company recorded share-based compensation expense and classified it in the unaudited condensed consolidated statements of operations as follows: SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE 2022 2021 For the three months ended March 31, 2022 2021 General and administrative $ 1,113,384 $ 1,092,228 Research and development 153,782 169,895 Total $ 1,267,166 $ 1,262,123
Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes the activity in the common stock equity classified compensatory warrants for the three months ended March 31, 2022: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 1,790,648 $ 1.52 $ 1.11 — $ 2.54 2.64 Granted to advisor and its designees — — Exercised — — Expired — — Forfeited — — Total outstanding – March 31, 2022 1,790,648 $ 1.52 $ 1.11 — 2.54 2.39 Exercisable 1,790,648 $ 1.52 $ 1.11 — $ 2.54 2.39 Non-Exercisable — $ — $ — — The following table summarizes the activity in the common stock equity classified compensatory warrants for the three months ended March 31, 2021: Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2020 1,294,217 $ 1.66 Granted — — Exercised (38,390 ) 2.09 Expired — — Forfeited (65,179 ) 2.07 Total outstanding – March 31, 2021 1,190,648 $ 1.61 Exercisable 1,187,052 $ 1.60 $ 1.11 2.54 4.00 Non-Exercisable 3,596 $ 2.54 $ 2.54 5.48
Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
SCHEDULE OF WARRANT ACTIVITY	The following table summarizes the noncompensatory equity classified warrant activity for the three months ended March 31, 2022: SCHEDULE OF WARRANT ACTIVITY Common Stock Shares Weighted– Average Exercise Price Range of Exercise Price Weighted– Average Remaining Life (Years) Total outstanding – December 31, 2021 5,549,137 $ 2.01 Legacy Ritter warrants — — Granted — — Exercised — — Expired — — Forfeited — — Total outstanding – March 31, 2022 5,549,137 $ 2.01 Exercisable 5,549,137 $ 2.01 $ 1.11 — $ 3.77 1.07 Non-Exercisable — $ — $ — —

QUARTERLY FINANCIAL DATA (UNA_2

QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)	3 Months Ended
	Mar. 31, 2022
Quarterly Financial Information Disclosure [Abstract]
SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS	SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS As reported Corrected For the Quarter Ended March 31, 2021 As reported Corrected Gain on change in fair value of warrant liabilities $ (2,122,900 ) $ (552,808 ) Net loss $ (3,672,627 ) $ (5,242,719 ) Net loss per common share $ (0.13 ) $ (0.19 )

SCHEDULE OF ACCOUNTS RECEIVABLE

SCHEDULE OF ACCOUNTS RECEIVABLE (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accounts Receivable	$ 642,306	$ 958,448
Less Allowances	(47,968)	(136,097)
Accounts receivable, net	$ 594,338	$ 822,351

SCHEDULE OF USEFUL LIVES OF PRO

SCHEDULE OF USEFUL LIVES OF PROPERTY AND EQUIPMENT (Details)	3 Months Ended
	Mar. 31, 2022
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	3 years
Molds and Tooling [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, useful life	5 years

ORGANIZATION AND SUMMARY OF S_4

ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ESTIMATES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Impairment losses on construction-in-progress	$ 0	$ 0
Other shipping and handling costs	39,000	30,000
Revenue	722,029	1,899,496
Allowance for estimated returns	43,000	0
Amortization of intangible assets	5,000	3,000
Accrued warranty liabilities	71,974		$ 60,281
Warranty costs	53,000	25,000
Warrant [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accrued warranty liabilities	72,000		60,000
Patents [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Carrying value	154,000		159,000
Accumulated amortization	325,000		320,000
Future estimated amortization, remaining nine months year ending December 31, 2022	14,000
Future estimated amortization, December 31, 2023	18,000
Future estimated amortization, December 31, 2024	15,000
Future estimated amortization, December 31, 2025	14,000
Future estimated amortization, December 31, 2026	14,000
Future estimated amortization, Thereafter	79,000
License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Carrying value	11,000		12,000
Accumulated amortization	408,000		$ 407,000
Amortization of intangible assets	2,000	2,000
Future estimated amortization, remaining nine months year ending December 31, 2022	6,000
Future estimated amortization, December 31, 2023	$ 5,000
Minimum [Member] | Patents and Licenses [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful lives	5 years
Maximum [Member] | Patents and Licenses [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful lives	17 years
License Revenue [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue	$ 0	478,654
License [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue		479,000
General Administrative Research and Development Expenses [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Other shipping and handling costs	$ 4,000	$ 1,000

LIQUIDITY (Details Narrative)

LIQUIDITY (Details Narrative) $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Securities Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from Issuance or Sale of Equity	$ 8,820

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Inventory Disclosure [Abstract]
Raw materials	$ 819,434	$ 823,315
Work in process	539,085	188,135
Finished goods	42,193	44,428
Total inventory	$ 1,400,712	$ 1,055,878

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets
Prepaid insurance	$ 818,216	$ 1,197,726
Prepaid manufacturing expenses	32,087	50,371
Other prepaid expenses	247,519	131,799
Prepaid expenses	$ 1,097,822	$ 1,379,896

SCHEDULE OF PROPERTY AND EQUIPM

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,613,869	$ 3,564,244
Less Accumulated depreciation	(3,383,627)	(3,360,324)
Property and equipment, net	230,242	203,920
Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	2,493,222	2,482,841
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	384,361	345,117
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	333,271	333,271
Molds and Tooling [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	260,002	260,002
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 143,013	$ 143,013

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 23,000	$ 15,000

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Board compensation	$ 17,500	$ 17,500
Franchise, sales and use taxes	11,975	14,090
Income taxes	4,356	3,620
Payroll	105,877	682,036
Professional fees	265,421	225,308
Research and development	293,624	232,712
Royalties	8,880	10,152
Vacation	313,633	282,910
Warranty liability	71,974	60,281
Other	250,135	265,292
Accrued liabilities	$ 1,343,375	$ 1,793,901

SCHEDULE OF WARRANTS ACTIVITY (

SCHEDULE OF WARRANTS ACTIVITY (Details) - Series C Warrants [Member] - Common Stock Warrants [Member] - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Number of Shares, Warrants Outstanding Beginning	2,481,614	3,378,596
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning	$ 0.72	$ 0.72
Exercisable Weighted Averag Remaining Contractual Term	2 years	2 years 9 months
Number of Shares, Warrants Exercised	(5,363)	(473,608)
Weighted Average Exercise Price Per Share Warrants Exercised	$ 0.72	$ 0.72
Number of Shares, Warrants Forfeited		36,097
Weighted Average Exercise Price Per Share Warrants Forfeited		$ 0.72
Number of Shares, Warrants Expired
Weighted Average Exercise Price Per Share Warrants Expired
Number of Shares, Warrants Granted
Weighted Average Exercise Price Per Share Warrants Granted
Number of Shares, Warrants Outstanding Ending	2,476,251	2,868,891
Weighted Average Exercise Price Per Share Warrants Outstanding Ending	$ 0.72	$ 0.72
Number of Shares, Warrants Exercisable	2,476,251	2,868,891
Weighted Average Exercise Price Per Share Exercisable	$ 0.72	$ 0.72
Range of Exercise Price, Exercisable	$ 0.72	$ 0.72
Exercisable Weighted Average Remaining Contractual Term	1 year 9 months 3 days
Number of Shares, Warrants Forfeited		(36,097)

SCHEDULE OF FAIR VALUE HIERARCH

SCHEDULE OF FAIR VALUE HIERARCHY FOR WARRANT LIABILITIES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Fair value for warrant liabilities	$ 1,686,200
Common Stock Warrant liabilities, Exercises	858	$ 1,570,092
Common Stock Warrant liabilities, Exercises	(858)	$ (1,570,092)
Change in fair value of warrant liabilities	(683,242)
Fair value for warrant liabilities	1,002,100
Fair Value, Inputs, Level 1 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value for warrant liabilities
Common Stock Warrant liabilities, Exercises
Common Stock Warrant liabilities, Exercises
Change in fair value of warrant liabilities
Fair value for warrant liabilities
Fair Value, Inputs, Level 2 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value for warrant liabilities
Common Stock Warrant liabilities, Exercises
Common Stock Warrant liabilities, Exercises
Change in fair value of warrant liabilities
Fair value for warrant liabilities
Fair Value, Inputs, Level 3 [Member]
Defined Benefit Plan Disclosure [Line Items]
Fair value for warrant liabilities	1,686,200
Common Stock Warrant liabilities, Exercises	858
Common Stock Warrant liabilities, Exercises	(858)
Change in fair value of warrant liabilities	(683,242)
Fair value for warrant liabilities	$ 1,002,100

SCHEDULE OF ASSUMPTIONS OF WARR

SCHEDULE OF ASSUMPTIONS OF WARRANT LIABILITIES (Details)	Mar. 31, 2022	Mar. 31, 2021
Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0	0
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	0.0203	0.0028
Minimum [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	88	81
Minimum [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	1 year 7 months 24 days	2 years 7 months 24 days
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	0.0229	0.0042
Maximum [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	101	84
Maximum [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	2 years 2 months 26 days	3 years 2 months 26 days
Weighted Average [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair value assumptions, measurement input, percentages	0.0208	0.0030
Weighted Average [Member] | Measurement Input, Price Volatility [Member]
Fair value assumptions, measurement input, percentages	90.4	83.52
Weighted Average [Member] | Measurement Input, Expected Term [Member]
Fair value assumptions, measurement input, term	1 year 9 months 3 days	2 years 9 months
Weighted Average [Member] | Measurement Input, Expected Dividend Rate [Member]
Fair value assumptions, measurement input, percentages	0	0

WARRANT LIABILITIES (Details Na

WARRANT LIABILITIES (Details Narrative) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Class of warrant or right, exercise price of warrants or rights		$ 1.32
Series C Warrants [Member]
Number of securities called by Each warrant or right	4,713,490
Class of warrant or right, exercise price of warrants or rights	$ 0.72
Series C Warrants [Member] | Minimum [Member]
Warrants and rights outstanding, term	1 year 8 months 12 days
Series C Warrants [Member] | Maximum [Member]
Warrants and rights outstanding, term	2 years 2 months 12 days

SCHEDULE OF EARNINGS PER SHARE

SCHEDULE OF EARNINGS PER SHARE BASIC AND DILUTED (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Earnings Per Share [Abstract]
Net loss used for basic earnings per share	$ (4,319,787)	$ (5,242,719)
Basic weighted-average common shares outstanding	35,294,051	28,165,796
Dilutive potential shares issuable from stock options and warrants
Diluted weighted-average common shares outstanding	35,294,051	28,165,796

SCHEDULE OF DILUTIVE SECURITIES

SCHEDULE OF DILUTIVE SECURITIES EXCLUDED FROM DILUTED NET LOSS PER SHARE (Details) - shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	14,680,055	13,886,590
Shares of Common Stock Subject to Outstanding Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	4,864,023	4,033,856
Shares of Common Stock Subject to Outstanding Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents	9,816,032	9,609,316
Shares of Common Stock Subject to Conversion of Series Alpha Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total common stock equivalents		243,418

SCHEDULE OF OPERATING LEASE RIG

SCHEDULE OF OPERATING LEASE RIGHT OF USE ASSETS AND OPERATING LEASE LIABILITIES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use assets	$ 1,645,568
Less amortization of operating lease right-of-use assets	(54,495)	$ (54,179)
Operating lease right-of-use assets	1,591,072
Operating lease liabilities, ending balance	1,640,358
Less non-current portion	(1,484,833)		$ (1,542,564)
Current portion at March 31, 2022	155,525		$ 134,091
Long term Operating Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating lease right-of-use assets	1,645,568
Less amortization of operating lease right-of-use assets	(54,496)
Operating lease right-of-use assets	1,591,072
Operating lease liabilities, beginning balance	1,676,655
Less principal payments on operating lease liabilities	(36,297)
Operating lease liabilities, ending balance	1,640,358
Less non-current portion	(1,484,833)
Current portion at March 31, 2022	$ 155,525

SCHEDULE OF MATURITIES OF OPERA

SCHEDULE OF MATURITIES OF OPERATING LEASE LIABILITIES (Details)	Mar. 31, 2022USD ($)
Commitments and Contingencies Disclosure [Abstract]
2022 (nine months)	$ 203,857
2023	368,341
2024	379,392
2025	390,773
2026	402,497
2027	379,165
Total	2,124,025
Less present value discount	(483,667)
Operating lease liabilities	$ 1,640,358

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative)	Apr. 05, 2022USD ($)	Dec. 15, 2021USD ($)ft²	Mar. 31, 2022USD ($)	Mar. 31, 2021USD ($)
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Area of Land | ft²		22,624
Lessee, Operating Lease, Term of Contract		61 months
Lessee, Operating Lease, Description		November 1, 2022 to November 30, 2027
Payments for Rent		$ 1,950,710
Tenant improvement allowance		339,360
Operating Lease, Weighted Average Remaining Lease Term			5 years 7 months 6 days
Operating Lease, Weighted Average Discount Rate, Percent			8.90%
Lease expense			$ 114,000	$ 86,000
Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Litigation Settlement, Amount Awarded to Other Party	$ 96,558
First Twelve Months [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Payments for Rent		$ 335,966

RESEARCH AND LICENSE AGREEMEN_2

RESEARCH AND LICENSE AGREEMENTS (Details Narrative) - USD ($)	Jan. 31, 2022	Apr. 30, 2022	Mar. 31, 2022	Feb. 28, 2021	Nov. 30, 2020	Jul. 31, 2020	Jun. 30, 2020	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Mar. 31, 2022	Mar. 31, 2021
Research and Development Expense											$ 1,864,745	$ 3,499,373
License cost											2,000	46,000
Product sales											722,029	1,899,496
Indefinite-Lived License Agreements	$ 150,000
Other Expenses	$ 160,000
License Revenue [Member]
Product sales											0	478,654
License [Member]
Product sales												479,000
License cost											310,000	0
University of Louisville Research Foundation [Member]
Research and Development Expense											0	69,000
Prediction Biosciences SAS [Member] | Collaborative Research Revenue [Member]
Product sales											0	0
Sekisui Diagnostics, LLC [Member]
Product sales											403,000	1,017,000
Yi Xin Zhen Duan Jishu Ltd [Member]
Product sales											0	38,000
Yi Xin Zhen Duan Jishu Ltd [Member] | License Revenue [Member]
Product sales											0	479,000
STA Pharmaceutical Co Ltd [Member]
Research and Development Expense											9,000	1,100,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member]
Regulatory marketing approval expenses										$ 500,000
Cumulative sales							$ 5,000,000
Research and Development Expense											184,000	107,000
License cost											0	0
Licensed product net sale							500,000,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Licensed Product Sales [Member]
Regulatory marketing approval expenses										5,000,000
Cumulative sales								$ 5,000,000
Regulatory marketing approval expenses										500,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 1 Clinical Trial [Member]
Milestone payment							50,000	50,000		100,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 2 Clinical Trial [Member]
Milestone payment							100,000	100,000		200,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Phase 3 Clinical Trial [Member]
Milestone payment							150,000	150,000		350,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Regulatory Marketing Approval [Member]
Licensed product net sale							300,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]
Milestone payment							50,000	50,000		100,000
Shortfall payments							5,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]
Milestone payment							5,000,000	5,000,000		5,000,000
Shortfall payments							$ 50,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Subsequent Event [Member]
Proceeds from convertible debt		$ 50,000
Regulatory marketing approval expenses		805,000
Patent costs		$ 200,000
Agreement term payment, description		In addition, the Company agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of anti-nucleolin agent-conjugated nanoparticles, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the last to expire of the licensed patents, (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2018, and (iv) payments ranging from $100,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Subsequent Event [Member] | Minimum [Member]
Shortfall payments		$ 10,000
License and Sponsored Research Agreements [Member] | University of Louisville Research Foundation [Member] | Subsequent Event [Member] | Maximum [Member]
Shortfall payments		$ 50,000
Sponsored Research and License Agreement [Member]
Research and Development Expense											87,000	62,000
License cost											55,000	36,000
Sponsored Research and License Agreement [Member] | University of Louisville Research Foundation [Member]
Regulatory marketing approval expenses			$ 2,700,000	$ 2,700,000				693,000
Agreement term payment, description						In July 2020, the Company entered into an exclusive license agreement with ULRF for RAS interaction inhibitor drug candidates. Under the agreement, the Company will take over development, regulatory approval and commercialization of the candidates from ULRF and is responsible for maintenance of the related intellectual property portfolio. In return, ULRF received approximately $112,000 for an upfront license fee and reimbursement of prior patent costs. In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patent, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to July 2020, and (iv) payments ranging from $50,000	In addition, the Company has agreed to pay ULRF (i) royalties, on patent-covered net sales associated with the commercialization of QN-165 as a treatment for COVID-19, of 4% (on net sales up to a cumulative $250,000,000) or 5% (on net sales above a cumulative $250,000,000), until expiration of the licensed patents, and 2.5% (on net sales for any sales not covered by Licensed Patents), (ii) 30% to 50% of any non-royalty sublicensee income received (50% for sublicenses granted in the first two years of the ULRF license agreement, 40% for sublicenses granted in the third or fourth years of the ULRF license agreement, and 30% for sublicenses granted in the fifth year of the ULRF license agreement or thereafter), (iii) reimbursements for ongoing costs associated with the preparation, filing, prosecution and maintenance of licensed patents, incurred prior to June 2020, and (iv) payments ranging from $50,000 to $5,000,000 upon the achievement of certain regulatory and commercial milestones.
Regulatory marketing approval expenses								300,000
Cumulative sales										$ 500,000,000
Licensed product net sale								500,000,000
License Agreement [Member] | University of Louisville Research Foundation [Member]
Upfront license fee							$ 24,000
License Agreement [Member] | University of Louisville Research Foundation [Member] | Minimum [Member]
Upfront license fee								20,000
License Agreement [Member] | University of Louisville Research Foundation [Member] | Maximum [Member]
Research and Development Expense					$ 430,000		$ 250,000
Upfront license fee								$ 100,000
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member]
Proceeds from convertible debt									$ 25,000
Cumulative sales									3,000,000
License cost											$ 0	$ 2,000
Licensed product net sale									$ 2,000,000
Agreement description									the Company entered into a license agreement with Advanced Cancer Therapeutics, LLC (“ACT”), granting the Company exclusive rights to develop and commercialize QN-165, an aptamer-based drug candidate.
Milestone payment for cumulative marketing expenses									$ 100,000
License Agreement [Member] | Advanced Cancer Therapeutics, LLC [Member] | CE Mark [Member]
Cumulative sales									500,000
Licensed product net sale									3,000,000
Milestone method revenue recognized									$ 100,000

SCHEDULE OF RESERVED SHARES (De

SCHEDULE OF RESERVED SHARES (Details)	Mar. 31, 2022shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	14,680,055
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	4,864,023
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total	9,816,032

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Weighted- average remaining contractual life (in Years), outstanding at ending	1 year 4 months 6 days
Employees and Non-employee Service Provider [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Number of shares, options outstanding, beginning	4,841,856	4,011,356
Range of exercise price, options outstanding	$ 6.07	$ 7.05
Weighted- Average Remaining Contractual Life (in Years), Outstanding, Beginning	8 years 6 months 7 days
Number of shares, options granted	25,000	27,000
Weighted average exercise price, options granted	$ 1.05	$ 3.29
Range of exercise price, options granted	$ 1.05	$ 3.29
Weighted- average remaining contractual life (in Years), options granted	9 years 9 months 14 days	9 years 10 months 28 days
Number of shares, options expired
Weighted average exercise price, options expired
Number of shares, options forfeited	(2,833)	(4,500)
Weighted average exercise price, options forfeited	$ 3	$ 3.68
Number of shares, options outstanding at ending	4,864,023	4,033,856
Weighted average exercise price, outstanding at ending	$ 6.05	$ 7.03
Weighted- average remaining contractual life (in Years), outstanding at ending	8 years 3 months 10 days	9 years 14 days
Number of shares, options exercisable (vested)	1,417,195	108,856
Range of exercise price, options exercisable (vested)	$ 10.83	$ 81.38
Weighted- average remaining contractual life (in Years), options exercisable (vested)	7 years 8 months 8 days	2 years 3 months 3 days
Number of shares, options non-exercisable (non-vested)	3,446,828	3,925,000
Weighted average exercise price, options non-exercisable (non-vested)	$ 4.08	$ 4.96
Weighted- average remaining contractual life (in Years), options Non-exercisable (non-vested)	8 years 6 months 25 days	9 years 2 months 23 days
Weighted- average remaining contractual life (in Years), outstanding at beginning		9 years 3 months 14 days
Weighted- average remaining contractual life (in Years), options forfeited		9 years 9 months 10 days
Employees and Non-employee Service Provider [Member] | Minimum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Range of exercise price, options outstanding	$ 1.24	$ 3.52
Range of Exercise price, Options Forfeited	1.24
Weighted average exercise price, outstanding at ending	1.05	3.52
Range of exercise price, options exercisable (vested)	3.29	4.97
Range of exercise price, options non-exercisable (non-vested)	1.05	3.29
Range of exercise price, options outstanding		3.29
Employees and Non-employee Service Provider [Member] | Maximum [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Range of exercise price, options outstanding	1,465.75	1,465.75
Range of Exercise price, Options Forfeited	4.97
Weighted average exercise price, outstanding at ending	1,465.75	4.97
Range of exercise price, options exercisable (vested)	1,465.75	1,465.75
Range of exercise price, options non-exercisable (non-vested)	$ 5.13	5.13
Range of exercise price, options outstanding		$ 1,465.75

SCHEDULE OF ASSUMPTIONS USED IN

SCHEDULE OF ASSUMPTIONS USED IN BLACK-SCHOLES OPTION-PRICING METHOD (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2020
Equity [Abstract]
Expected dividend yield	0.00%	0.00%
Expected stock-price volatility	102.00%	102.00%
Risk-free interest rate, minimum	1.58%	0.84%
Risk-free interest rate, maximum	1.67%	1.04%
Expected average term of options (in years)	6 years	6 years
Share price	$ 1.05	$ 3.29	$ 4.07

SCHEDULE OF SHARE-BASED COMPENS

SCHEDULE OF SHARE-BASED COMPENSATION EXPENSE (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Total	$ 1,267,166	$ 1,262,123
General and Administrative Expense [Member]
Total	1,113,384	1,092,228
Research and Development Expense [Member]
Total	$ 153,782	$ 169,895

SCHEDULE OF WARRANT ACTIVITY (D

SCHEDULE OF WARRANT ACTIVITY (Details) - $ / shares	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Warrants Outstanding Beginning	5,549,137
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning	$ 2.01
Number of shares, warrants granted
Weighted average exercise price per share warrants granted
Number of Shares, Warrants Exercised
Weighted average exercise price per share warrants exercised
Number of Shares, Warrants Expired
Weighted average exercise price per share warrants expired
Number of Shares, Warrants Forfeited
Weighted average exercise price per share warrants forfeited
Number of Shares, Warrants Outstanding Ending	5,549,137
Weighted Average Exercise Price Per Share Warrants Outstanding Ending	$ 2.01
Weighted average remaining life (Years) exercisable	1 year 25 days
Number of Shares, Warrants Exercisable	5,549,137
Weighted Average Exercise Price Per Share Exercisable	$ 2.01
Number of shares, warrants non-exercisable
Weighted Average Exercise Price Per Share Non-Exercisable
Exercisable non- vested per share
Number of shares, warrants exercised
Number of shares, warrants forfeited
Share based compensation arrangement by share based payment award non option equity instruments legacy ritter
Share based compensation arrangement by share based payment award non option equity instruments legacy ritter weighted average exercise price
Number of shares, warrants expired
Number of shares, warrants exercisable	5,549,137
Weighted average exercise price per share exercisable	$ 2.01
Number of shares, warrants non-exercisable
Weighted average exercise price per share non-exercisable
Minimum [Member] | Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable vested per share	1.11
Maximum [Member] | Non Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercisable vested per share	$ 3.77
Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares, Warrants Outstanding Beginning	1,790,648	1,294,217
Weighted Average Exercise Price Per Share Warrants Outstanding Beginning	$ 1.52	$ 1.66
Weighted Average Remaining Life (Years) - outstanding	2 years 7 months 20 days
Number of shares, warrants granted
Weighted average exercise price per share warrants granted
Number of Shares, Warrants Exercised		38,390
Weighted average exercise price per share warrants exercised		$ 2.09
Number of Shares, Warrants Expired
Weighted average exercise price per share warrants expired
Number of Shares, Warrants Forfeited		65,179
Weighted average exercise price per share warrants forfeited		$ 2.07
Number of Shares, Warrants Outstanding Ending	1,790,648	1,190,648
Weighted Average Exercise Price Per Share Warrants Outstanding Ending	$ 1.52	$ 1.61
Weighted average remaining life (Years) exercisable	2 years 4 months 20 days	4 years
Number of Shares, Warrants Exercisable	1,790,648	1,187,052
Weighted Average Exercise Price Per Share Exercisable	$ 1.52	$ 1.60
Number of shares, warrants non-exercisable		3,596
Weighted Average Exercise Price Per Share Non-Exercisable		$ 2.54
Exercisable non- vested per share		$ 2.54
Number of shares, warrants exercised		(38,390)
Number of shares, warrants forfeited		(65,179)
Weighted average remaining life (Years) non-exercisable		5 years 5 months 23 days
Number of shares, warrants expired
Number of shares, warrants exercisable	1,790,648	1,187,052
Weighted average exercise price per share exercisable	$ 1.52	$ 1.60
Number of shares, warrants non-exercisable		3,596
Weighted average exercise price per share non-exercisable		$ 2.54
Compensatory Warrant Activity [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise price - beginning	1.11
Range of exercise price - ending	1.11
Exercisable vested per share	1.11	1.11
Compensatory Warrant Activity [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Range of exercise price - beginning	2.54
Range of exercise price - ending	2.54
Exercisable vested per share	$ 2.54	$ 2.54

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Dec. 31, 2020	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 03, 2021	Nov. 29, 2021	Aug. 31, 2020	Jul. 31, 2020	May 31, 2020	Dec. 31, 2017
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares reserved for future issuance		14,680,055
Series Alpha convertible preferred stock, shares outstanding		0		0
Compensation cost		$ 1,300,000	$ 1,300,000
Unrecognized compensation cost		$ 6,900,000
Cost is expected to be recognized over a weighted average period		1 year 4 months 6 days
Exercise price of warrants				$ 1.32
Warrants to purchase shares	2,191,010			600,000	300,000
Fair value of warrants		$ (683,242)	$ (552,808)	$ 300,000
Share price	$ 4.07	$ 1.05	$ 3.29
Compensatory Warrant Activity [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Unrecognized compensation cost			$ 0
2020 Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares reserved for future issuance		3,500,000
Equity Option [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares reserved for future issuance		4,864,023
Stock option granted exercise price		$ 0.84
Equity Option [Member] | 2020 Stock Incentive Plan [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares reserved for future issuance		2,786,990		2,809,157
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number		4,770,167		4,748,000
Stock options description		The exercise price for an option issued under the 2020 Plan is determined by the Board of Directors, but will be (i) in the case of an incentive stock option (A) granted to an employee who, at the time of grant of such option, is a 10% stockholder, no less than 110% of the fair market value per share on the date of grant; or (B) granted to any other employee, no less than 100% of the fair market value per share on the date of grant; and (ii) in the case of a non-statutory stock option, no less than 100% of the fair market value per share on the date of grant.
Compensatory Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Proceeds from issuance or sale of equity		$ 4,000,000
Purchase of warrants		811,431								668,024
Exercise price of warrants		$ 1.11								$ 2.34
Noncompensatory Equity Classified Warrants [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants								780,198	270,478
Exercise price of warrants				$ 1.11		$ 2		$ 0.001	$ 1.11
Warrants to purchase shares				270,478		5,399,517
Fair value of warrants				$ 2,300,000
Warrants xercised	200,000
Noncompensatory Equity Classified Warrants [Member] | Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants	1,000,000							1,920,678
Exercise price of warrants	$ 0.01						$ 6	$ 5.25
Noncompensatory Equity Classified Warrants [Member] | Warrant [Member] | Investor [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Purchase of warrants							1,287,829

SCHEDULE OF ERROR CORRECTIONS A

SCHEDULE OF ERROR CORRECTIONS AND PRIOR PERIOD ADJUSTMENTS (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021
Gain on change in fair value of warrant liabilities	$ (683,242)	$ (552,808)	$ 300,000
Net loss	$ (4,319,787)	$ (5,242,719)
Net loss per common share	$ (0.12)	$ (0.19)
Previously Reported [Member]
Gain on change in fair value of warrant liabilities		$ (2,122,900)
Net loss		$ (3,672,627)
Net loss per common share		$ (0.13)
Revision of Prior Period, Error Correction, Adjustment [Member]
Gain on change in fair value of warrant liabilities		$ (552,808)
Net loss		$ (5,242,719)
Net loss per common share		$ (0.19)

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Apr. 29, 2022	Apr. 25, 2022	Dec. 31, 2021	Dec. 03, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Purchase of warrants			600,000	300,000	2,191,010
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 1.32
Subsequent Event [Member]
Subsequent Event [Line Items]
Purchase of warrants		600,000
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.60
Subsequent Event [Member] | Series B Preferred Stock [Member]
Subsequent Event [Line Items]
Preferred Stock, Shares Authorized	381,786
Nominal value NIS per share	$ 0.01
Preferred Stock, Value, Outstanding	$ 600,000
Preferred Stock, Voting Rights	53% interest in the voting securities
Subsequent Event [Member] | Series B Preferred Stock [Member] | Funding Agreement [Member]
Subsequent Event [Line Items]
Agree to fund aggregate upto	$ 10,400,000
Subsequent Event [Member] | Series A-1 Preferred Stock [Member]
Subsequent Event [Line Items]
Purchase of warrants	2,432,203
Preferred Stock, Shares Authorized	2,232,861
Nominal value NIS per share	$ 0.01
Warrants exchange	3,500,000